In the preceding three months, 7 analysts have released ratings for AnaptysBio (NASDAQ:ANAB), presenting a wide array of perspectives from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 2 | 4 | 1 | 0 | 0 |
| Last 30D | 0 | 1 | 0 | 0 | 0 |
| 1M Ago | 0 | 2 | 0 | 0 | 0 |
| 2M Ago | 0 | 0 | 1 | 0 | 0 |
| 3M Ago | 2 | 1 | 0 | 0 | 0 |
In the assessment of 12-month price targets, analysts unveil insights for AnaptysBio, presenting an average target of $50.0, a high estimate of $80.00, and a low estimate of $28.00. Surpassing the previous average price target of $30.00, the current average has increased by 66.67%.
Investigating Analyst Ratings: An Elaborate Study
A comprehensive examination of how financial experts...
ログインすると全部閲覧できます。
ログイン